Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Johnson & Johnson — PDUFA Date: Caplyta | Humanexa Signals | Humanexa Signals

Catalyst

Johnson & Johnson — PDUFA Date: Caplyta

Johnson & Johnson — PDUFA Date — Caplyta in Major depressive disorder.

Strategic implication

MDD approval would significantly expand Caplyta commercial footprint.

Date

August 5, 2026

Phase

NDA/BLA

Status

confirmed

Signal score

7.4

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.